


Hemoptysis and hematemesis: age and vaccine distribution, VAERS data* (U.S. and foreign), 1990.07–2024.08.30[†]

Draft v32.5



	Janssen COVID-19	Moderna COVID-19	Pfizer/BioNTech COVID-19	Unknown manufacturer COVID-19	All COVID-19 2020.12.14–2024.08.30	All non-COVID-19 1990.07–2020.12.13
n VAERS IDs	176	497	1265	2	1941	519
μ , Mean ^{‡‡}	50.3	56.6	53.4	40.0	54.0	27.2
\hat{x} , Median ^{‡‡}	51.0	59.0	56.0	40.0	56.0	18.0
σ , Standard deviation ^{‡‡}	19.1	19.4	22.4	—	21.4	27.6
γ , Skewness ^{‡‡}	0.1	-0.3	-0.1	—	-0.2	-0.2
n Hospitalized	76	208	546	2	833	212
n Life threatening	48	122	283	0	453	83
n Recovered	38	117	243	0	398	218
n Not recovered	100	221	723	2	1046	150
n Died	24	73	161	0	258	40

*Terms queried in SYMPTOM fields 1–5 include: hemoptysis and hematemesis.

[†]Onset of symptoms post vaccine. n IDs are all COVID-19.

[‡]Natural language processing was used to extract age values from SYMPTOM TEXT and fill in missing data. Remaining reports with unknown age are neither plotted, nor included in calculations, but are included in subtotals. Symbols have a random adjustment within $\sim \pm 0.5$ yr. ^{‡‡}Symbols link to OpenVAERS.

*VAERS disclaimer (excerpts): "... VAERS is designed to rapidly detect unusual or unexpected patterns of adverse events, also referred to as 'safety signals'. If a possible safety signal is found ..., further analysis is performed with other safety systems, such as [CDC's VSD & CISA, or FDA BEST]. vaers.hhs.gov